By marking #BPDCNday, Menarini Group is giving a rare and aggressive blood cancer nowhere to hide
Together, we make a difference
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy that often manifests with skin lesions.
Although BPDCN is mostly diagnosed in elderly patients, it may occur at any age,1,2 with men three times more likely to be affected than women. There are roughly 700 cases in the United States and 1000 in Europe.3
BPDCN not only presents as skin lesions but also has a hematologic component. Its similarity to other blood cancers has contributed to its frequent misdiagnoses and very poor prognosis. This highlights the urgent need to raise awareness of the disease to ensure proper diagnosis and better outcomes for patients.
People need to know about BPDCN.
We at Menarini Group are proud to actively support Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Disease Awareness Day (#BPDCNday) as part of our unwavering commitment to make a difference in the lives of patients with cancer.
People with BPDCN need early diagnosis
So what can we do to improve the situation for patients with BPDCN?
Speeding up diagnosis may be a very important weapon when we are fighting back against BPDCN.
The diagnosis and care of BPDCN is a joint effort between dermatologists, pathologists, and hematologist-oncologists. By working together, they can avert potential misdiagnoses.
Recently, a specific protein (CD123) was identified as a way to diagnose BPDCN.* The date 1/23—the 1st month and 23rd day of the year is aimed to strengthen the key role of CD123 for a correct BPDCN diagnosis.
Menarini Group commits to raising awareness of BPDCN
With #BPDCNday, our aim is to raise awareness in the medical community and unite patients and healthcare professionals in the fight against this disease. We hope you will join us in supporting patients and families affected by BPDCN around the world.
We at Menarini Group believe that working together can make real changes. We also know that the medical professionals and patients dealing with BPDCN are committed to the fight against BPDCN.
Learn more about BPDCN at: www.bpdcninfo.com
Watch our YouTube channel
*BPDCN can include other markers, such as TCL1, TCF4, and CD303 (BDCA2).4,5
- Facchetti F et al. Mod Pathol. 2016 Feb;29(2):98-111.
- Sapienza MR et al. Haematologica. 2019 Apr;104(4):729-737.
- Sullivan JM, Rizzieri DA. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):16-23.
- Pagano L et al. Br J Haematol. 2016 Jul;174(2):188-202.
- Ceribelli M et al. Cancer Cell. 2016 Nov 14;30(5):764-778.